Royal Free Hospital


Klinik

Standort der Organisation:
London, Großbritannien (UK)


Publikationen in Kooperation mit FAU-Wissenschaftlerinnen und Wissenschaftlern


Go to first page Go to previous page 1 von 2 Go to next page Go to last page
Anthony, L., Kulke, M., Caplin, M., Bergsland, E., Oberg, K., Pavel, M.E.,... Jiang, W. (2019). Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials. In PANCREAS (pp. 428-428). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Klompmaker, S., Peters, N.A., Van Hilst, J., Bassi, C., Boggi, U., Busch, O.R.,... Roeyen, G. (2019). Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis. Annals of Surgical Oncology, 26(3). https://dx.doi.org/10.1245/s10434-018-07101-0
Wu, W., Jordan, S., Graf, N., Pena, J.D.O., Curram, J., Allanore, Y.,... Puttini, P.S. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 78(5), 648-656. https://dx.doi.org/10.1136/annrheumdis-2018-213455
Dromain, C., Pavel, M.E., Ruszniewski, P., Langley, A., Massien, C., Baudin, E., & Caplin, M.E. (2019). Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer, 19(1). https://dx.doi.org/10.1186/s12885-018-5257-x
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R.T., Knigge, U.P.,... Wiedenmann, B. (2019). Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology, 108(1), 18-25. https://dx.doi.org/10.1159/000493319
Ahrens, M., Scheich, S., Goekbuget, N., Boleti, E., Gruenwald, V., Escudier, B.,... Bergmann, L. (2018). A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). (pp. 73-73).
Kremer, A., Bowlus, C.L., Neff, G.W., Aspinall, R., Galambos, M.R., Goel, A.,... Boudes, P. (2018). Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study. (pp. 1464A-1465A).
Hoersch, D., Kulke, M.H., Caplin, M.E., Anthony, L.B., Bergsland, E., Oberg, K.,... Pavel, M.E. (2018). Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period. (pp. 341-342).
Pavel, M.E., Cwikla, J., Wolin, E., Phan, A., Raderer, M., Sedlackova, E.,... Caplin, M. (2018). Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension. (pp. 310-310).
Wolin, E.M., Pavel, M.E., Cwikla, J.B., Phan, A.T., Raderer, M., Sedlackova, E.,... Caplin, M.E. (2018). Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study. (pp. 358-359).
Lopez-Isac, E., Acosta-Herrera, M., Assassi, S., Simeon, C.P., Carreira, P.E., Castellvi, I.,... Martin, J. (2018). NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY. (pp. 189-189).
Mathew, N.R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M.,... Zeiser, R. (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine. https://dx.doi.org/10.1038/nm.4484
Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S.,... Jones, D. (2018). Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. In JOURNAL OF HEPATOLOGY (pp. S105-S106). Paris, FR: AMSTERDAM: ELSEVIER SCIENCE BV.
Weickert, M.O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M.E., Valle, J.W.,... Kulke, M.H. (2018). Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (pp. 357-358).
Lopez-Isac, E., Bossini-Castillo, L., Palma, A.B., Assassi, S., Mayes, M.D., Simeon, C.P.,... Martin, J. (2017). Analysis of ATP8B4 F436L missense variant in a large Systemic sclerosis cohort. Arthritis and Rheumatology. https://dx.doi.org/10.1002/art.40058
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L.,... Krieg, T. (2017). European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401-1424. https://dx.doi.org/10.1111/jdv.14458
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L.,... Krieg, T. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(10), 1581-1594. https://dx.doi.org/10.1111/jdv.14466
Pavel, M.E., Gable, J., Kulke, M.H., Bergsland, E., Anthony, L.B., Caplin, M.E.,... Hudgens, S. (2017). Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. (pp. 238-238).
Cwikla, J.B., Wolin, E.M., Pavel, M.E., Phan, A.T., Raderer, M., Sedlackova, E.,... Caplin, M. (2017). Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension.
Connor, T.M., Hoer, S., Mallett, A., Gale, D.P., Gomez-Duran, A., Posse, V.,... Maxwell, P.H. (2017). Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. Plos Genetics, 13(3), e1006620. https://dx.doi.org/10.1371/journal.pgen.1006620

Zuletzt aktualisiert 2016-06-06 um 13:39